Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Vincent B. Nieuwenhuijs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9311-8208; OpenAlex author ID A5112748028. Sources: OpenAlex.

Their work

Papers
27 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 2 papers · 2024: 7 papers · 2025: 5 papers · 2026: 5 papers

Papers 27

  1. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  2. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  3. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  4. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  5. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  6. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  7. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  8. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  9. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  10. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  11. Nutritional support in pancreatic cancer patients and its effect on nutritional status: an observational regional HPB network study investigating current pract… Co-author DOI 10.1007/s00520-024-08683-0↗
  12. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Last author DOI 10.1093/jnci/djae070↗
  13. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  14. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  15. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Last author DOI 10.1245/s10434-023-14704-9↗
  16. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  17. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  18. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗
  19. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101909↗
  20. Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.09.004↗
  21. Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis. Co-author DOI 10.1097/sla.0000000000004093↗
  22. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  23. Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. Co-author DOI 10.1245/s10434-022-11831-7↗
  24. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  25. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Co-author DOI 10.1016/j.ejso.2020.11.145↗
  26. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Co-author DOI 10.1093/bjs/znab345↗
  27. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. Co-author DOI 10.1016/j.hpb.2019.06.019↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 18 shared papers, 2020–2026 · strength 2.48
  2. Ignace H. J. T. de Hingh · 18 shared papers, 2020–2026 · strength 2.48
  3. Hjalmar C. van Santvoort · 18 shared papers, 2020–2026 · strength 2.48
  4. Marc G. Besselink · 18 shared papers, 2020–2026 · strength 2.48
  5. Bert A. Bonsing · 17 shared papers, 2020–2026 · strength 2.37
  6. Martijn W.J. Stommel · 17 shared papers, 2020–2026 · strength 2.30
  7. Geert Kazemier M · 16 shared papers, 2020–2026 · strength 2.25
  8. Izaak Quintus Molenaar · 16 shared papers, 2020–2026 · strength 2.15
  9. Vincent Erwin de Meijer · 16 shared papers, 2020–2026 · strength 2.15
  10. Lois A. Daamen · 13 shared papers, 2021–2026 · strength 1.85
  11. Sebastiaan Festen · 13 shared papers, 2021–2026 · strength 1.85
  12. Martijn Intven · 11 shared papers, 2021–2026 · strength 1.59
  13. Robert C. Verdonk · 10 shared papers, 2022–2026 · strength 1.50
  14. Vincent P. Groot · 9 shared papers, 2022–2026 · strength 1.35
  15. Iris W.J.M. van Goor · 7 shared papers, 2021–2026 · strength 1.17
  16. Gert J. Meijer · 6 shared papers, 2022–2026 · strength 0.99
  17. Thijs J. Schouten · 7 shared papers, 2021–2026 · strength 0.97
  18. Paul C. M. Andel · 5 shared papers, 2024–2026 · strength 0.92
  19. Casper H.J. van Eijck · 6 shared papers, 2020–2026 · strength 0.82
  20. J. Sven D. Mieog · 5 shared papers, 2021–2025 · strength 0.71
  21. Judith de Vos‐Geelen · 5 shared papers, 2020–2026 · strength 0.65
  22. Johanna W. Wilmink · 4 shared papers, 2020–2026 · strength 0.59
  23. Babs M. Zonderhuis · 4 shared papers, 2021–2025 · strength 0.55
  24. Geertjan van Tienhoven · 3 shared papers, 2025–2026 · strength 0.52
  25. Gijs A. Patijn · 3 shared papers, 2023–2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.